roman-sinichkin-shutterstock-com-drugs-

Roman Sinichkin / Shutterstock.com

11 July 2016Americas

USFDA says Amgen’s Humira biosimilar meets ‘highly similar’ threshold

The US Food and Drug Administration (FDA) has said that an Amgen biosimilar is indeed “highly similar” to AbbVie’s drug Humira (adalimumab) in a document released for the advisory committee panel meeting due to be held tomorrow.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB